SVB Wealth LLC decreased its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 13.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 61,995 shares of the biopharmaceutical company’s stock after selling 9,404 shares during the period. SVB Wealth LLC’s holdings in Bristol Myers Squibb were worth $3,344,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in BMY. Vanguard Group Inc. lifted its stake in Bristol Myers Squibb by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 198,727,768 shares of the biopharmaceutical company’s stock valued at $10,719,376,000 after buying an additional 2,743,759 shares during the period. State Street Corp grew its position in shares of Bristol Myers Squibb by 2.0% during the 3rd quarter. State Street Corp now owns 96,595,232 shares of the biopharmaceutical company’s stock worth $4,356,445,000 after buying an additional 1,855,238 shares during the period. Dimensional Fund Advisors LP increased its stake in shares of Bristol Myers Squibb by 11.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 18,143,672 shares of the biopharmaceutical company’s stock valued at $818,105,000 after acquiring an additional 1,873,618 shares during the last quarter. Legal & General Group Plc raised its position in shares of Bristol Myers Squibb by 8.4% in the 3rd quarter. Legal & General Group Plc now owns 17,075,743 shares of the biopharmaceutical company’s stock valued at $770,116,000 after acquiring an additional 1,317,199 shares during the period. Finally, Pzena Investment Management LLC raised its position in shares of Bristol Myers Squibb by 0.4% in the 3rd quarter. Pzena Investment Management LLC now owns 14,901,604 shares of the biopharmaceutical company’s stock valued at $672,062,000 after acquiring an additional 58,129 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.
Insider Transactions at Bristol Myers Squibb
In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of Bristol Myers Squibb stock in a transaction dated Wednesday, April 1st. The stock was sold at an average price of $61.67, for a total value of $1,850,100.00. Following the sale, the executive vice president owned 159,248 shares of the company’s stock, valued at $9,820,824.16. This trade represents a 15.85% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 0.05% of the company’s stock.
Analyst Ratings Changes
Read Our Latest Analysis on Bristol Myers Squibb
Bristol Myers Squibb Price Performance
NYSE BMY opened at $56.10 on Monday. The company has a debt-to-equity ratio of 2.10, a quick ratio of 1.28 and a current ratio of 1.42. The stock has a market cap of $114.56 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 0.16 and a beta of 0.26. The business has a 50 day simple moving average of $59.28 and a 200 day simple moving average of $54.91. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89.
Bristol Myers Squibb (NYSE:BMY – Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to analysts’ expectations of $10.93 billion. During the same quarter in the prior year, the company earned $1.80 earnings per share. The business’s quarterly revenue was up 2.6% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. Analysts anticipate that Bristol Myers Squibb Company will post 6.3 earnings per share for the current fiscal year.
Bristol Myers Squibb Announces Dividend
The business also recently announced a quarterly dividend, which was paid on Friday, May 1st. Investors of record on Thursday, April 2nd were paid a $0.63 dividend. The ex-dividend date of this dividend was Thursday, April 2nd. This represents a $2.52 dividend on an annualized basis and a yield of 4.5%. Bristol Myers Squibb’s dividend payout ratio is presently 70.79%.
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Tapestry Stock Drops After Strong Quarter and Raised Outlook
- 3 Companies Quietly Essential to Data Center and AI Operations
- Beyond NVIDIA: Picks-and-Shovels AI Plays with Strong Momentum
- Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
